Trial Profile
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2018
Price :
$35
*
At a glance
- Drugs Levodopa (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Acorda Therapeutics; Civitas Therapeutics
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
- 20 Apr 2016 Results published in an Acorda media release.
- 19 Apr 2016 Results published in the Movement Disorders